September 19, 2008 – Last month, MIV announced continued positive results for VESTAsync, a polymer-free drug-eluting ...
Stents Drug Eluting
This channel includes news and new technology innovations for drug eluting stents (DES). These drug coated stents were developed to solve a frequent problem with bare metal stents, which can cause neointimal hyperplasia (scar tissue growth) in some patients. The antiproliferative drugs used on DES prevent the growth of tissue. One downside of DES is the requirement for patients to take long-term antiplatelet therapy to prevent the possible formation of clots on these stents. Newer generation DES use technologies help the vessels heal faster, which may allow reduce the duration of dual antiplatelet therapy (DAPT), or use a single drug, usually eliminating aspirin. This section includes news for both metallic and bioresorbable drug-eluting stents and related clinical trial data.
September 17, 2008 - Medtronic Inc. said this week it started two new trials of the Endeavor Resolute drug-eluting stent ...
September 16, 2008
September 11, 2008 -Cook Medical has completed enrollment in the first international clinical trial of a first-of ...
September 10, 2008The FDA recently cleared Boston Scientific Corp.’s PROMUS Everolimus-Eluting Coronary Stent System.
Boston Scientific ...
September 09, 2008September 5, 2008 - The results of the SYNTAX study, a head-to-head comparison between drug-eluting stents (DES) using ...
September 04, 2008The FDA recently cleared Boston Scientific Corp.’s PROMUS Everolimus-Eluting Coronary Stent System and Abbott Vascular’s ...
September 03, 2008Feature | Venkat Rajan, medical research analyst, Frost & Sullivan
This comparison chart features three categories of stents: coronary, carotid and peripheral. We gratefully acknowledge ...
September 03, 2008September 2, 2008 - The safety debate about drug-eluting stents (DES) is still ongoing and in these times of uncertainty ...
September 02, 2008September 2, 2008 – Boston Scientific Corp. today announced positive one-year results from the European and ...
September 01, 2008September 2, 2008 - Data from the landmark SYNTAX trial indicates patients with very complex coronary artery disease can ...
September 01, 2008September 2, 2008 - Patients with both diabetes and advanced blockages in at least three heart vessels will find good ...
September 01, 2008August 28, 2008 – In patients with diabetes, the CYPHER Sirolimus-eluting coronary stent outperformed the Taxus stent ...
August 27, 2008August 27, 2008 - Cordis Corp. today said it received CE mark approval to market the CYPHER SELECT Plus Sirolimus ...
August 26, 2008Medtronic Inc. recently announced the initiation of the first investigational sites in the U.S. to participate in ...
August 25, 2008August 25, 2008 - A study conducted by the Cardiovascular Research Institute, Washington Hospital Center, Washington, D ...
August 24, 2008© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now